Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02227199
Title Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University of Washington
Indications

Hodgkin's lymphoma

Therapies

Brentuximab vedotin + Carboplatin + Etoposide + Ifosfamide

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.